• Quest Diagnostics (DGX) on Tuesday edged to a new record high, taking out the previous record high posted on March 10, 2025.
• Quest has rallied sharply since releasing a positive earnings report on April 22, 2025.
• Quest has benefited post-earnings from a hike in analyst price targets by an average of 2.4%.

Company Description:

Quest Diagnostics (DGX) is a provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions, and other clinical laboratories. The company operates roughly 2,000 patient locations in the U.S., and its products and services are used by customers on six continents. The company has a market cap of $20 billion. 

Today’s Context:

Quest Diagnostics on Tuesday extended the post-earnings rally to edge to a new record high.  The current rally began with a positive earnings report on April 22, when Quest’s earnings and revenue beat analyst expectations and Quest maintained its full-year guidance. Q1 net revenue rose by 12% year-over-year. Since the earnings report, analysts have generally issued favorable commentary on the company and have boosted their price targets for the stock. A Baird analyst, who has an “Outperform” rating on the stock, said that “DGX continues to feel easy in a difficult stock market.”

What I’m Watching: 

Quest Diagnostics closed 1.03% higher on Tuesday, posting a new record high and bringing the six-session rally to a total of 10.3%. I found today’s Chart of the Day by using Barchart’s New Highs & Lows page and selecting stocks that have new 52-week highs. I then viewed the stocks on the list with the Flipcharts feature. 

What Comes Next: 

The record high signals the possibility of further gains, although it always pays to watch for any temporary downside correction. A downside correction could be used for an entry point.

Key Technical Levels for Quest Diagnostics: 

Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.

• The Parabolic Time/Price (50) trading system issued a “Buy” signal on April 22 and has been long since then.
• Barchart’s Overall Average Opinion is an 88% “Buy.”
• All the Barchart Opinion indicators were a “Buy” as of Tuesday, April 29, except the 20-50 day moving average crossover system.
• Quest has been above the 200-day moving average for just over a year, since April 2024.

Analyst Ratings on Quest Diagnostics: 

• Wall Street analysts have a consensus rating of a “Moderate Buy” with a rating of 4.06 out of 5, and price targets between $160 and $200.
• The average price target of $186 is above Tuesday’s close of $178.50, suggesting the stock has 4.2% appreciation potential relative to current levels, assuming analysts are not being too cautious with their price targets.

Why It Matters: 

A breakout to a major new high can suggest that a stock has underlying strength to push the stock even higher, although caution is always warranted.

Want more insights like this? Stay tuned for tomorrow’s Chart of the Day!

Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance and reevaluate your stop losses at least on a weekly basis.